ORGANTRANS
European (EU) H2020 funded ORGANTRANS project is set to develop a disruptive solution that enables the 3D printing of tissue-engineered constructs. Coordinated by CSEM, eight consortium members will create a standardized and automated tissue preparation and maturation platform, which will provide patients with End-Stage Liver Disease (ESLD) an alternative to donor organ transplants.
Related Press
22 February 2024
CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants
The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....
24 June 2021
CUTISS
CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has unveiled the world’s first automated machine to produce customized skin tissue...
3 February 2023
Making personalized cancer therapies accessible to all
CSEM has supported Lausanne-based start-up Limula in its mission to make cell therapies more affordable, and to facilitate access to these personalized treatments. ...